Related Experiment Video

Updated: Jun 19, 2026

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat
07:46

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat

Published on: June 4, 2012

Increased prevalence of and associated mortality with methicillin-resistant Staphylococcus aureus among hospitalized

Geoffrey C Nguyen1, Harshna Patel, Rachel Y Chong

  • 1Mount Sinai Hospital IBD Centre, Department of Medicine, University of Toronto Faculty of Medicine, Toronto, Ontario, Canada. geoff.nguyen@utoronto.ca

The American Journal of Gastroenterology
|October 8, 2009
PubMed
Abstract

Insights

Hospitalized patients with inflammatory bowel disease (IBD) face a higher risk of methicillin-resistant Staphylococcus aureus (MRSA) infection. This increased risk is linked to greater mortality, highlighting the need for infection prevention strategies.

Area of Science:

  • Infectious Diseases
  • Gastroenterology
  • Hospital Epidemiology

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) is a growing concern in hospital settings.
  • The specific impact of MRSA on hospitalized patients with inflammatory bowel disease (IBD) remains largely unknown.

Purpose of the Study:

  • To investigate the prevalence and outcomes of MRSA infections in hospitalized IBD patients.
  • To compare MRSA risk and mortality in IBD patients versus non-IBD gastrointestinal and general medical inpatients.

Main Methods:

  • Utilized the Nationwide Inpatient Sample (NIS) database from 1998-2004.
  • Identified 116,842 IBD admissions and compared MRSA prevalence and in-hospital mortality.
  • Adjusted for confounders including length of stay and comorbidities.

Main Results:

  • MRSA prevalence significantly increased over the study period.
  • IBD patients had a higher risk of MRSA compared to non-IBD GI and general medical patients.
  • MRSA infection was associated with a sevenfold increase in mortality among IBD patients, with catheter-related infections being more common.

Conclusions:

  • Hospitalized IBD patients are at an elevated risk for MRSA infections.
  • MRSA is associated with increased mortality in the IBD population.
  • Emphasizes the critical need for nosocomial infection prevention and reducing hospitalization length for IBD patients.

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Staphylococcal Skin Infections01:29

Staphylococcal Skin Infections

Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Dysbiosis of the Gut Microbiota01:18

Dysbiosis of the Gut Microbiota

The human gut microbiome includes a diverse array of microbial species, including beneficial commensals and opportunistic pathogens, which interact to support host health. These microbes contribute to essential functions such as nutrient metabolism, immune system modulation, and maintenance of intestinal barrier integrity. However, disruptions to this equilibrium—referred to as dysbiosis—can have widespread physiological consequences.Dysbiosis is often characterized by reduced microbial...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...